Short answer
UTAH MEDICAL PRODUCTS INC (UTMD) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $9M (down 10.2% year over year) with net income of $3M.
Q1 2026 key financials · XBRL
- Revenue
- $9M
- −10.2% YoY
- Net income
- $3M
- −14.4% YoY
- Operating margin
- 29.4%
- Gross margin
- 60.6%
- EPS (diluted)
- $0.82
- −10.9% YoY
Source: XBRL data from the UTAH MEDICAL PRODUCTS INC (UTMD) Q1 2026 10-Q on SEC EDGAR. USD.
UTAH MEDICAL PRODUCTS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- 1Q revenue $8.722M, down 10.2% YoY from $9.710M
- Gross margin 60.6% vs 57.0%; operating margin 29.4% vs 32.5%
- Best line Gynecology/Electrosurgery/Urology $5.228M, up from $4.896M; worst Blood Pressure Monitoring $1.019M vs $1.807M
- Operating cash flow $3.109M vs $4.464M; cash and investments $87.406M, up $1.649M sequentially
- Outlook: regain OUS business hindered by trade policies; pursue new biopharma sales, acquisitions, dividends and repurchases
Risk Factors
- No risk-factors section provided; only share-repurchase disclosures
- Open-market repurchases: 2,196 shares at average $58.58 during 1Q 2026
- Repurchase activity depends on seller availability and stock price
- Liquidity allocation: excess cash used for ongoing share repurchases since 1992
- Listing risk: repurchases constrained to preserve Nasdaq Global Market listing
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other UTAH MEDICAL PRODUCTS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.